PORT-6

N/A

Report date: 2024/03/06 11:29:32
NME

Base Information

Drug NamePORT-6
Drug Alias NamePORT-6TT-10
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAdenosine A2a receptor antagonists
TargetsAdenosine A2a receptor
Therapy Area/IndicationsProstatic Neoplasms, Castration-ResistantEndometrial NeoplasmsCarcinoma, Non-Small-Cell Lung +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesImpetis Biosciences Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPortage Biotech Inc
Inactive CompaniesTarus Therapeutics Inc
Active IndicationsProstatic Neoplasms, Castration-ResistantEndometrial NeoplasmsCarcinoma, Non-Small-Cell Lung +[7] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A